Bristol Myers Squibb Raises Full-Year Guidance Amid Growth Portfolio Strength
Bristol Myers Squibb (BMY) reported strong third-quarter results, driven by double-digit growth within its key growth portfolio. Following these results, CEO Christopher Boerner announced that the company is raising its full-year guidance to reflect current momentum. Looking ahead, management provided long-term financial outlooks, signaling a non-GAAP EPS range of $6.35-$6.55 for 2026. The company is also proactively preparing for a significant revenue transition in 2027, as it anticipates an annual revenue step-down of approximately $1.5 billion to $2 billion from the blockbuster drug Eliquis.
Tickers: $BMY
Topics: earnings report guidance increase revenue growth
Read the full article at Seeking Alpha
Part of the story Capri Holdings Reports Q2 2027 Earnings Beat and Raises Full-Year Guidance (16 articles)